[1]严克敏,朱惠娟,龚凤英.雷公藤红素:一种潜在的治疗肥胖症的新药物[J].国际内分泌代谢杂志,2017,37(01):32-34，47.[doi:10.3760/cma.j.issn.1673-4157.2017.01.09]
　Yan Kemin,Zhu Huijuan,Gong Fengying..Celastrol:a potential and novel drug for obesity[J].International Journal of Endocrinology and Metabolism,2017,37(01):32-34，47.[doi:10.3760/cma.j.issn.1673-4157.2017.01.09]
点击复制

雷公藤红素:一种潜在的治疗肥胖症的新药物()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年01期
页码:
32-34，47
栏目:
综述
出版日期:
2017-01-20

文章信息/Info

Title:
Celastrol:a potential and novel drug for obesity
作者:
严克敏; 朱惠娟; 龚凤英
100730 北京,中国医学科学院,北京协和医学院,北京协和医院内分泌科,国家卫生和计划生育委员会内分泌重点实验室,协和转化医学中心
Author(s):
Yan Kemin;  Zhu Huijuan;  Gong Fengying.
Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medic
关键词:
雷公藤红素;  瘦素;  HSF1-PGC1α轴;  核因子-κB;  肥胖症
Keywords:
Celastrol;  Leptin;  HSF1-PGC1α axis;  Nuclear factor-κB;  Obesity Fund program:National Natural Science Foundation of China
DOI:
10.3760/cma.j.issn.1673-4157.2017.01.09
摘要:
雷公藤红素是存在于传统中药雷公藤根部的一种苯醌甲基三萜系化合物。近几年的研究发现,雷公藤红素能够减少摄食量、增加能量消耗,从而发挥强效的减重作用。其作用机制包括激活瘦素受体-信号转导与转录激活因子3信号通路和减轻下丘脑内质网应激,从而加强瘦素的作用; 通过激活热休克因子1-过氧化物酶体增殖物活化受体γ协同刺激因子1α(HSF1-PGC1α)轴,促进能量代谢; 通过抑制核因子-κB信号通路,改善胰岛素抵抗。雷公藤红素的上述作用使其有望成为未来治疗肥胖症的一种新药物。
Abstract:
Celastrol is a pentacyclic triterpene extracted from the roots of the traditional Chinese medicine Tripterygium Wilfordi(thunder god vine)plant. Recent studies demonstrated that celastrol could suppress food intake and increase energy expenditure thus playing a powerful role in losing weight. The detailed mechanisms included activating the leptin receptor-signal transducer and activator of transcription 3 signal pathway and reducing hypothalamic endoplasmic reticulum stress to potentiate leptin's effect, activating heat shock factor 1-peroxisome proliferator-activated receptor γ coactivator-1α axis to promote energy metabolism and inhibiting nuclear factor κB signal pathway to improve insulin resistance. All of these findings make celastrol as a potential novel drug to treat obesity in the future.

参考文献/References:

[1] Djalalinia S, Qorbani M, Peykari N,et al. Health impacts of obesity[J]. Pak J Med Sci,2015,31(1):239-242. DOI: 10.12669/pjms.311.7033.
[2] Finkelstein EA, Khavjou OA, Thompson H,et al. Obesity and severe obesity forecasts through 2030[J].Am J Prev Med,2012,42(6):563-570. DOI: 10.1016/j.amepre.2011.10.026.
[3] Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations[J].Drugs,2015,75(9):935-945. DOI: 10.1007/s40265-015-0410-1.
[4] Kim JE, Lee MH, Nam DH,et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice[J].PLoS One,2013,8(4):e62068. DOI: 10.1371/journal.pone.0062068.
[5] Liu J, Lee J, Salazar Hernandez MA,et al. Treatment of obesity with celastrol[J].Cell,2015,161(5):999-1011. DOI: 10.1016/j.cell.2015.05.011.
[6] Ma X, Xu L, Alberobello AT,et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis[J].Cell Metab,2015,22(4):695-708. DOI: 10.1016/j.cmet.2015.08.005.
[7] Wang C, Shi C, Yang X,et al. Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism[J].Eur J Pharmacol,2014,744:52-58. DOI: 10.1016/j.ejphar.2014.09.043.
[8] Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer[J].Cancer Lett,2011,303(1):9-20. DOI: 10.1016/j.canlet.2010.10.025.
[9] Ramírez S, Claret M. Hypothalamic ER stress: a bridge between leptin resistance and obesity[J].FEBS Lett,2015,589(14):1678-1687. DOI: 10.1016/j.febslet.2015.04.025.
[10] Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism[J].Acta Biochim Biophys Sin(Shanghai),2011,43(4):248-257. DOI: 10.1093/abbs/gmr007.
[11] Jia G, Aroor AR, DeMarco VG,et al. Vascular stiffness in insulin resistance and obesity[J].Front Physiol,2015,6:231. DOI: 10.3389/fphys.2015.00231.
[12] Abu Bakar MH, Cheng KK, Sarmidi MR,et al. Celastrol protects against antimycin a-induced insulin resistance in human skeletal muscle cells[J].Molecules,2015,20(5):8242-8269.DOI: 10.3390/molecules20058242.
[13] Bakar MH, Sarmidi MR, Kai CK,et al. Amelioration of mitochondrial dysfunction-induced insulin resistance in differentiated 3T3-L1 adipocytes via inhibition of NF-κB pathways[J].Int J Mol Sci,2014,15(12):22227-22257. DOI: 10.3390/ijms151222227.
[14] Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease[J]. Cell Metab, 2011,13(1):11-22.DOI:10.1016/j.cmet.2010.12.008.
[15] Crescenzo R, Bianco F, Mazzoli A, et al. Mitochondrial efficiency and insulin resistance[J].Front Physiol, 2014,5:512.DOI:10.3389/fphys.2014.00512.

相似文献/References:

[1]常海瑶,刘晶,吴文昊,等.血管生成素样蛋白6、瘦素与糖尿病肾病的关系[J].国际内分泌代谢杂志,2020,40(05):289.[doi:10.3760/cma.j.cn121383-20200208-02009]
　Chang Haiyao,Liu Jing,Wu Wenhao,et al.Relationship between angiogenin-like protein 6, leptin and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2020,40(01):289.[doi:10.3760/cma.j.cn121383-20200208-02009]
[2]王姝洁,张翼飞,张志国.雷公藤红素在治疗代谢综合征中的作用及相关机制[J].国际内分泌代谢杂志,2017,37(04):258.
　Wang Shujie,Zhang Yifei,Zhang Zhiguo..Effects and related mechanisms of celastrol in the treatment of metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2017,37(01):258.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(30540036,30771026,81370898); 北京市自然科学基金资助项目(7082079); 人社部留学人员科技活动项目择优资助经费(启动类); 国家临床重点专科建设项目单位(WBYZ2011-873) 通信作者:龚凤英,Email:fygong@sina.com
更新日期/Last Update: 2017-01-20